Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 10/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.50 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748 | 1.00 | CYP4Z1 (0.50) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL9346882 | 0.83 | CYP4Z1 (0.50) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL1757403 | 0.83 | CYP4Z1 (0.50) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL14359614 | 0.80 | CYP4Z1 (0.48) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL6388692 | 0.80 | CYP4Z1 (0.58) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL5851764 | 0.79 | CYP4Z1 (0.57) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL4866578 | 0.79 | CYP4Z1 (0.53) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL28547818 | 0.79 | CYP4Z1 (0.44) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL4865106 | 0.78 | CYP4Z1 (0.52) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 | |
| SCHEMBL16639135 | 0.76 | CYP4Z1 (0.55) | CYP4Z1CYP1A2CYP2C8CYP2B6CYP4F8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-111526660-B | Copper foil with carrier and copper foil substrate | 长春石油化学股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111526660-A | Carrier-attached copper foil and copper foil substrate | 长春石油化学股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3555104-A1 | NRF2 COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109646-A1 | NRF2 COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | CYP4Z1 4320/4885CYP1A2 3682/4885CYP2C8 1783/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | CYP4Z1 2224/4885CYP1A2 181/4885CYP2C8 301/4885 |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | CYP4Z1 4289/4885CYP1A2 1198/4885CYP2C8 2906/4885 |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | CYP4Z1 4289/4885CYP1A2 1198/4885CYP2C8 2906/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | CYP4Z1 550/4885CYP1A2 465/4885CYP2C8 373/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | CYP4Z1 4264/4885CYP1A2 1194/4885CYP2C8 2936/4885 |
| US-20090270625-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | CYP4Z1 4283/4885CYP1A2 1257/4885CYP2C8 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.